Bovie Medical receives FDA marketing clearance for BOSS bipolar sintered steel coagulation device

Mar 19 2010

Bovie Medical Corporation (the “Company”) (NYSE-AMEX Symbol: BVX), a manufacturer and marketer of electrosurgical products, today announced the Company received clearance from the Food and Drug Administration (FDA) to market its proprietary BOSS™ bipolar sintered steel coagulation device. The BOSS™ is the latest device based on Bovie’s saline enhanced sintered steel technology.

“Receiving FDA clearance to market the BOSS™ is a significant milestone in Bovie’s development of disposable high margin proprietary products for fast growing markets.”

The BOSS™ delivers RF energy simultaneously with saline to perform coagulation of soft tissue and bone resulting in reduced blood loss while minimizing charring and sticking of tissue. Saline enhanced surgeries reduce operating time while improving post-operative outcomes leading to shortened recovery time.

The BOSS™ will primarily be targeted to orthopedic surgeons performing hip and knee arthroplasty; a market comprised of approximately 1.1 million procedures performed annually in the United States. These orthopedic procedures represent large and growing markets due to a more active and aging population. Additional markets for the BOSS™ include spine, endoscopic, abdominal and thoracic surgeries. The worldwide market is expected to exceed $500 million in 2010.

Andrew Makrides, president of Bovie, stated, “Receiving FDA clearance to market the BOSS™ is a significant milestone in Bovie’s development of disposable high margin proprietary products for fast growing markets.”